In common with small-molecule approaches to targeted cancer therapy, antibody therapeutics have conventionally been designed to target mitogenic or pro-survival pathways aberrantly activated or differentially overexpressed in cancer cells as compared with that in normal cells.
It had been designed to target Iran's Natanz nuclear plant.
Various therapeutic interventions have been designed to target delayed injury.
Its chairman, Massoud Shadjareh, said it had been designed to target and profile Muslim children.
Both have been designed to target the thymidine kinase gene of the ILTV genome.
Hh inhibitors have been designed to target the signalling elements and so disable signalling.
More elegant and highly specific medicines have been designed to target certain immune mediators of the adaptive immune system.
Several radioligands have been designed to target TSPO and have been studied in-vivo in AD populations.
Many drugs have been designed to target the canonical NF-κB signaling pathway with limited success, potentially due to the nonspecificity of the drugs for other kinases and the interaction of canonical signaling with other pathways.
Homogeneous HDS strategies using well-defined molecular catalysts have been designed to target these recalcitrant S-heterocycles; however, the formation of stable transition metal sulfide complexes following C S bond activation has largely prevented catalytic turnover.
Diversified nanoparticles have been designed to target GBM surface markers, overexpressed receptors, aberrant genes and signalling pathways, in addition to contemplating barriers targeting strategies.
